XOMA Stock News 3.84 05/13/2014 16:23:10 Xoma Ltd (XOMA)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Xoma Ltd (XOMA) 3.84 $XOMA

XOMA to Present at the Bank of America Merrill Lynch Health Care Conference
GlobeNewswire - Mon May 12, 2:31PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today Paul Rubin, the Company's Senior Vice President, Research and Development & Chief Medical Officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference on May 14, 2014, at 3:40 p.m. PT.

XOMA Posts Wider Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 3:00PM CDT
XOMA Corporation (XOMA) posts wider-expected loss in the first quarter of 2014.

Why XOMA Corp. Shares Tanked
Sean Williams, The Motley Fool - Motley Fool - Thu May 08, 4:46PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of XOMA , a biopharmaceutical company focused...

Hot Stock: XOMA, Shares Drop 9.7% (XOMA)
Comtex SmarTrend(R) - Thu May 08, 12:45PM CDT
XOMA (NASDAQ:XOMA) is one of today's worst performing low-priced stocks, down 9.7% to $3.80 on 1.1x average daily volume. XOMA has traded 2.2 million shares thus far today, vs. average volume of 2.1 million shares per day. The stock has underperformed the Dow (-9.7% to the Dow's 0.5%) and underperformed the S&P 500 (-9.7% to the S&P's 0.3%) during today's trading.

XOMA Reports First Quarter 2014 Operational Highlights and Financial Results
GlobeNewswire - Wed May 07, 3:47PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its operational highlights and financial results for the first quarter ended March 31, 2014.

Acute Coronary Syndrome - Pipeline Review, H1 2014: 21 Companies and 29 Drugs Profiled
M2 - Wed May 07, 12:15PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2f56rx/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Bayer AG - CSL Limited - GlaxoSmithKline plc - LG Life Sciences, Ltd. - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - Ligand Pharmaceuticals, Inc. - MedImmune, LLC - Medicure Inc. - Pfizer Inc. - Regado Biosciences, Inc. - Stealth Peptides Inc. - The Medicines Company - Viron Therapeutics, Inc. - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles: - cangrelor - rivaroxaban - BAY-818781 - REG-1 - clopidogrel bisulfate - VT-111a - CSL-112 - gevokizumab - losmapimod - MTP-131 - ZK-001 - PR-15 - temanogrel hydrochloride - MDCO-216 - losmapimod - LC-231306 - ACP-501 - PF-06282999 - Artpep-2 - DMI-4983 - LA-8045 - COR-3 - COR-2 - AEM-28 - Type 5 Adenylyl Cyclase Inhibitors - tirofiban hydrochloride transdermal - Liver X Receptor Modulator For Acute Coronary Syndrome - Anti Platelet Program - SD-970 For more information visit http://www.researchandmarkets.com/research/2f...e_coronary

Positive Data, Financial Results, and Drug Development Programs - Analyst Notes on Novavax, Ironwood, XOMA, Luminex and Amicus
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novavax, Inc. (NASDAQ: NVAX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), XOMA Corporation (NASDAQ: XOMA), Luminex Corporation (NASDAQ: LMNX) and Amicus Therapeutics, Inc. (NASDAQ: FOLD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1940-100free.

Technical Data on Top Gainers -- Research on XOMA, ServiceNow, Ctrip.com, and Splunk
PR Newswire - Thu May 01, 3:26AM CDT
The US markets saw a positive sentiment on Tuesday, April 29, 2014, with the NASDAQ Composite closing at 4,103.54, up 0.72%, the Dow Jones Industrial Average ending the session at 16,535.37, up 0.53% and the S&P 500 finishing 0.48% higher at 1,878.33. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including XOMA Corp. (NASDAQ: XOMA), ServiceNow Inc. (NYSE: NOW), Ctrip.com International Ltd (NASDAQ: CTRP) and Splunk Inc. (NASDAQ: SPLK). Free technical research on XOMA, NOW, CTRP and SPLK can be downloaded upon signing up at:

XOMA to Announce First Quarter 2014 Financial Results and Host Webcast on May 7
GlobeNewswire - Wed Apr 30, 12:25PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Wednesday, May 7, 2014, at 4:30 p.m. Eastern time to discuss first quarter 2014 financial results and provide an update on gevokizumab's global clinical programs.

Biotech and the Fallacy of Analyst Ratings
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 30, 11:05AM CDT
The health-care sector can be volatile, and it's oftentimes not for the faint of heart. While there are tried-and-true conglomerates such as Johnson & Johnson , and big pharmaceutical companies like Pfizer can deliver somewhat predictable...

Why XOMA, Zillow, and Novavax Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 4:15PM CDT
High hopes for earning season continued to fuel the S&P 500 upward on Tuesday, with the broad-based index advancing for the ninth time in the past 11 sessions. Economic data, on the other hand, was good, but not great. First up, The...

Why XOMA Corp. Shares Popped
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 12:30PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of XOMA , a biopharmaceutical company engaged...

Why XOMA (XOMA) Stock Is Surging Today
at The Street - Tue Apr 29, 11:35AM CDT
XOMA (XOMA) was upgraded to 'buy' by analysts at MLV & Co following the announcement of Phase 3 gevo trials.

Hot Stock: XOMA, Shares Gain 18.1% (XOMA)
Comtex SmarTrend(R) - Tue Apr 29, 10:41AM CDT
XOMA (NASDAQ:XOMA) is one of today's best performing low-priced stocks, up 18.1% to $4.51 on 1.0x average daily volume. Thus far today, XOMA has traded 2.4 million shares, vs. average volume of 2.3 million shares per day. The stock has outperformed the Dow (18.1% to the Dow's 0.5%) and outperformed the S&P 500 (18.1% to the S&P's 0.4%) during today's trading.

Upgrade Alert for XOMA (XOMA)
Comtex SmarTrend(R) - Tue Apr 29, 6:57AM CDT
XOMA (NASDAQ:XOMA) was upgraded from Hold to Buy at MLV & Co. today. The stock closed yesterday at $3.82 on volume of 2.0 million shares, below average daily volume of 2.3 million. XOMA share prices have moved between a 52-week high of $9.57 and a 52-week low of $3.02 and closed yesterday at 26% above that low price at $3.82 per share. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 3.4%.

Global Uveitis Therapeutics Pipeline Review 2014 - Analysis of 20 Companies & 30 Drug Profiles
M2 - Mon Apr 28, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6t3qv8/uveitis) has announced the addition of the "Uveitis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Uveitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Uveitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Uveitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Alcon, Inc. - pSivida Corp. - Inovio Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - Apitope International NV - Novartis AG - TheraKine Ltd. - Enzo Biochem, Inc. - Can-Fite BioPharma Ltd. - Regeneron Pharmaceuticals, Inc. - XOMA Corporation - HanAll Biopharma Co., Ltd. - TxCell SA - Endocyte, Inc. - Janssen Biotech, Inc. - Icon Bioscience, Inc. - Eleven Biotherapeutics - Clearside BioMedical, Inc. - AbbVie Inc. - Panoptes Pharma Ges.m.b.H. Drug Profiles - sirolimus - adalimumab - voclosporin - fluocinolone acetonide - gevokizumab - sarilumab - secukinumab - CF-101 - triamcinolone acetonide - LFG-316 - Optiquel - interferon gamma-1b - ustekinumab - triamcinolone acetonide - VGX-1027 - HL-036 - PA-2612 - EBI-006 - ATX-UV2 - P-13 - IBI-70090 - EC-1669 - TNP-470 - PP-001 - EBI-028 - Col-Treg - ATX-UV1 - Narrow Spectrum Kinase Inhibitors - OPK-20018 - INV-17 For more information visit http://www.researchandmarkets.com/research/6t3qv8/uveitis

XOMA Finalizes Plans for Gevokizumab Phase 3 Clinical Program in Pyoderma Gangrenosum
GlobeNewswire - Mon Apr 28, 8:00AM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that based on its meeting with the U.S Food and Drug Administration (FDA), the Company is finalizing its plans for a gevokizumab Phase 3 program in pyoderma gangrenosum (PG), a rare neutrophilic dermatosis of painful expanding necrotic skin ulcers. During the meeting, the Company and the FDA reviewed the data generated from XOMA's pilot trial in six PG patients. The pilot study was designed to determine if gevokizumab, an IL-1 beta modulating antibody, should be explored in pivotal studies in patients with active PG. XOMA is incorporating the FDA's verbal and written responses regarding the clinical design of the studies into a final Phase 3 program, which it will submit to the Agency for any final comments.

The Recent Performance of 'Baker Brother Biotech Stocks' is Awful
at The Street - Tue Apr 15, 11:23AM CDT
Healthcare's most closely followed hedge fund is losing money during the biotech bubble burst.

XOMA Shares Down 17.9% Since SmarTrend's Sell Call (XOMA)
Comtex SmarTrend(R) - Tue Apr 01, 9:46AM CDT
SmarTrend identified a Downtrend for XOMA (NASDAQ:XOMA) on March 6th, 2014 at $6.75. In approximately 4 weeks, XOMA has returned 17.93% as of today's recent price of $5.54.

XOMA Down 17.5% Since SmarTrend Downtrend Call (XOMA)
Comtex SmarTrend(R) - Tue Mar 25, 9:23AM CDT
SmarTrend identified a Downtrend for XOMA (NASDAQ:XOMA) on March 6th, 2014 at $6.75. In approximately 3 weeks, XOMA has returned 17.48% as of today's recent price of $5.57.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 114

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 108

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 92

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 207

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 37

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 27

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 159

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 52

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 95

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 93

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading

Top 5 Most Recently Viewed Articles

Trustmark Corporation Schedules Fourth Quarter Earnings Call

Updated Category News Views 204

Trustmark Corporation Plans Q4 Financial Results Announcement Trustmark Corporation (NASDAQGS:TRMK) is set to announce its fourth quarter financial results soon. The announcement will take place through a news release after the market closes. The company plays a vital role in the financial sector with its diverse offerings. Conference Call for Financial Discussion On the...

Continue Reading
VSee Health Experiences Significant Stock Surge After Approval

Updated Category News Views 271

VSee Health Inc. Stock Surges Over 45% Recently, VSee Health Inc. (NASDAQ: VSEE) experienced an impressive jump in its stock price, increasing by 45.28% to reach $1.54 during after-hours trading. This surge marks a notable uptick from its closing price of $1.06 earlier in the day, which represented a remarkable rise of 71.66% according to market data. Impact of Federal...

Continue Reading
Exciting Grand Opening for New Homes in Dacono, CO

Updated Category News Views 193

Exciting Grand Opening for New Homes in Dacono, CO Century Communities, Inc. (NYSE: CCS), a leading national homebuilder celebrated for its innovative approach to online home sales, is thrilled to unveil a Grand Opening event at Sweetgrass in Dacono. This event marks the debut of the community's stunning new model home, bringing an exciting opportunity for potential...

Continue Reading
Shakumoto Housei's Kickstarter: Artisan Neckties Unite People

Updated Category News Views 162

Shakumoto Housei's Journey to Craft Neckties with Heart In today's fast-paced world of fashion, Shakumoto Housei, a cherished small necktie manufacturer from Japan, is embarking on a unique adventure. This family-operated firm aims to connect with the global community through a heartfelt Kickstarter project. Rather than merely producing neckties, the initiative represents...

Continue Reading
Beko's Call for Sustainable Refrigeration in Food Security

Updated Category News Views 108

Refrigeration's Crucial Role in Global Food Security This year's World Food Day theme, 'Right to Foods for a Better Life and a Better Future', emphasizes the importance of worldwide access to food, highlighting the often-overlooked role of refrigeration. A recent report underscores that insufficient and unreliable refrigeration contributes significantly to food spoilage,...

Continue Reading